Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Immunol. 2013 Jul 19;191(5):2089–2095. doi: 10.4049/jimmunol.1203476

Figure 3. BLyS levels.

Figure 3

A.) Plasma BLyS concentrations were significantly greater in IPF subjects (n=110) than in either COPD (n=90) or normals (n=53). B.) Among the IPF cohort, BLyS levels were highest among those who died during the next year (n=25), and in those who had pulmonary artery hypertension (PAH) (n=17), compared to those with lesser pulmonary artery (PA) mean pressures (Nl) (n=28). PAH was defined as PA mean pressures >25 mmHg with PA wedge (PAW) pressures <15 mmHg. Subjects with PAW >15 were not tabulated here (n=5). These five excluded subjects had PA mean pressures >25, and their BLyS concentrations were 1.92±0.32 ng/ml). C.) BLyS concentrations were correlated with pulmonary artery pressures among IPF subjects. D.) The quartile (25%) of IPF subjects with greatest BLyS levels (High) had worse outcomes than those subjects with lesser BLyS levels (Low). Cross-hatches and numbers in parentheses denote censored events (end of observation). E.) Absolute mortality was also greater among IPF patients with the highest quartile plasma BLyS concentrations (High) after omission of the subpopulation that had lung transplantations during the observation interval.